Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

Addition of lenalidomide to R-B is highly active in untreated MCL patients, but associated with unexpected high rates of infections and SPMs.